Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.
|
22322613 |
2012 |
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Glioblastoma with PNET-like components has a higher frequency of isocitrate dehydrogenase 1 (IDH1) mutation and likely a better prognosis than primary glioblastoma.
|
22076165 |
2011 |
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Independent analysis of the publically available TCGA glioblastoma dataset confirmed our strong association between cMYC and mutant IDH1 expression.
|
23934175 |
2013 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We sought to determine the impact of surgical resection on survival after controlling for IDH1 status in malignant astrocytomas-World Health Organization grade III anaplastic astrocytomas and grade IV glioblastoma.
|
24305719 |
2014 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Currently, there are limited prognostic markers of glioblastoma including IDH1, ATRX, MGMT, PTEN, EGFRvIII, and others.
|
29372493 |
2018 |
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The total NADPH production capacity in glioblastoma was provided for 65% by IDH activity and the occurrence of IDH1 (R132 ) mutation reduced this capacity by 38%.
|
20127344 |
2010 |
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Thus, our work suggests that elevated ECM stiffness can independently foster glioblastoma aggression and contribute to glioblastoma recurrence via bypassing the protective activity of IDH1 mutational status.
|
27820599 |
2016 |
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Multivariate analysis revealed age, Karnofsky performance score, extent of tumor resection, first-line treatment, year of diagnosis, and MGMT promoter methylation status were associated with survival in patients with IDH1(R132H) -nonmutant glioblastoma.
|
27088883 |
2016 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients.
|
26934681 |
2016 |
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Addition of 2-HG to glioblastoma cultures recapitulates the effects of the IDH mutation on intrinsic apoptosis, shuts down oxidative phosphorylation and reduces ATP levels in glioblastoma cells.
|
29057925 |
2017 |
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: A multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status.
|
28302331 |
2017 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The recent 2016 WHO classification for CNS tumors categorizes diffuse glioma into two major types that include IDH wild-type glioblastoma, which is the predominant type and IDH-mutant glioblastoma, which is less common and displays better prognosis.
|
28730141 |
2017 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, having access to IDH1 wild-type glioblastoma of patients with exceptionally long recurrence free survival (RFS), we decided to compare their mutational and gene expression profile to groups of IDH1 wild-type glioblastoma of patients with shorter RFS, by using NGS technology.
|
29844869 |
2018 |
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We sought to confirm this impression by analyzing vessels in glioblastoma previously examined using chromogenic in situ hybridization (CISH) for EGFR and immunohistochemistry for mutant IDH1.
|
22298889 |
2012 |
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The combination of IDH1 mutations and MGMT methylation outperforms either IDH1 mutations or MGMT methylation alone in predicting survival of glioblastoma patients.
|
24510240 |
2014 |
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Morphologic patterns of noncontrast-enhancing tumor in glioblastoma correlate with IDH1 mutation status and patient survival.
|
28988652 |
2018 |
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy (cIMPACT-NOW) has recommended that isocitrate dehydrogenase 1 and 2 wildtype (IDH1/2wt) diffuse lower-grade gliomas (LGGs) WHO grade II or III that present with a) a telomerase reverse transcriptase promoter mutation (pTERTmt), and/or b) gain of chromosome 7 combined with loss of chromosome 10, and/or c) epidermal growth factor receptor (EGFR) amplification should be reclassified as diffuse astrocytic glioma, IDH1/2-wildtype, with molecular features of glioblastoma, WHO grade IV (IDH1/2wt astrocytomas WHO IV).
|
31637414 |
2019 |
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, given that the effect of mutant IDH1 was not recapitulated in glioblastoma cells, the enhancement of JQ1 sensitivity by IDH1 mutation seems to be specific for ICC cells.
|
30156013 |
2018 |
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Overexpression of IDH1(R132H) and IDH2(R172K) mutant protein in glioblastoma cells resulted in increased radiation sensitivity and altered ROS metabolism and suppression of growth and migration in vitro.
|
23115158 |
2013 |
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
No significant difference was observed in the frequency of amplification of these genes in primary and secondary glioblastomas or in glioblastomas with and without IDH1 mutations, suggesting that amplification of PDGFRA, KIT and KDR may be implicated in the pathogenesis of a small fraction of both subtypes of glioblastoma.
|
21382095 |
2011 |
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Expression of R132H mutational IDH1 in human U87 glioblastoma cells affects the SREBP1a pathway and induces cellular proliferation.
|
23011765 |
2013 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
T1+Gad performed best for IDH typing of glioblastoma (sensitivity 91.9%, specificity 100%, AUC 0.945) and ADC for non-Gadolinium-enhancing gliomas (sensitivity 85.7%, specificity 78.4%, AUC 0.877).
|
30927935 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In turn, tumor purity is prognostic in IDH1 wild-type GBM.<b>Implications:</b> Tumor purity is an independent prognostic marker in glioblastoma and is associated with the extent of MGMT methylation.<i></i>.
|
28148826 |
2017 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
No survival difference was noted between patients with glioblastoma harboring the SNP and patients with IDH wild type glioblastoma.
|
29423539 |
2018 |
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We initially screened 86 unselected high-grade astrocytomas, followed by 174 IDH1-R132H1 immunonegative glioblastomas derived from patients aged 60 years and older enrolled in the Nordic phase III trial of elderly patients with newly diagnosed glioblastoma.
|
27626492 |
2016 |